Counsel acting for the plaintiff in the case – Joseph Bayer – filed for dismissal without any settlement payment from GSK, which was named as a defendant in the suit. The company said that it “welcomes this outcome and believes the dismissal of Mr Bayer’s case is the correct result.”
Shares in GSK and other companies that have been involved in selling Zantac (ranitidine) over the years came under pressure last week, after analysts said liability litigation could end up costing billions of dollars to resolve.
